Abstract library

8 results for "CA 19-9".
#1233 CA 19-9: A Novel Role in the Prognosis of Pancreatic Neuroendocrine Tumors
Introduction: Prognostication is difficult for neuroendocrine tumours given their long survival. Staging, grading using Ki67 and receptor status are tools commonly used, but are not without their limitations. CA 19-9 is a tumour marker used in the diagnosis and follow-up of pancreatic adenocarcinomas despite multiple confounding factors, including jaundice. CA 19-9 is not useful in the diagnosis of PNETs having a sensitivity of only 19%, but it is not known whether it has other roles in PNETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Logan Mills
Authors:
Keywords: CA 19-9
#1434 CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Kaizhou Jin
Authors:
#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
Authors:
#369 Carcinoid Tumor of Common Bile Duct (CBD) Misdiagnosed as Cholangiocarcinoma
Introduction: Carcinoid tumors of the bile duct are extremely rare. Unlike cholangiocarcinoma, they grow more slowly and generally occur in younger patients and in females. They have better prognosis and greater disease free survival.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Nasim Valizadeh
Authors:
#719 Mixed Exocrine-Endocrine Pancreatic Tumors
Introduction: Mixed pancreatic tumors are very rare, characterized by association of exocrine (ductal or acinar) and endocrine components, and positivity for neuroendocrine (NE) markers in >30% of cells.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: professor Claudio Pasquali
Authors:
#769 Surgicial Management of Gastroenteropancreatic Neuroendocrine Tumors: Early and Long-Term Results
Introduction: Surgery could improve survival of gastroenteropancreatic neuroendocrine tumors (GEP NET). Nevertheless, data on survival prognostic factors come from studies focusing on heterogeneous population including both resected and non-resected patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Nadia Russolillo
Authors:
Keywords: GEP-NET, surgery
#793 Experience of a Single Italian Center with NET Patients
Introduction: The management of neuroendocrine tumors involves a multidisciplinary approach, so in 2004 the Endocrinology and Metabolic Unit developed a local/regional network to manage NET patients and to increase physician awareness of the disease.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Franco Grimaldi
Authors:
#2170 Clinical Characteristics and Prognostic Analysis of 14 Patients with Gastric Mixed Adenoneuroendocrine Carcinoma
Introduction: To investigate the clinical characteristics and prognostic factors of patients with gastric mixed adenoneuroendocrine carcinoma(MANEC).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Xu Bei
Authors: